Individualized vaccines for cancer

US11248264B2 · kind B2 · utility

Assignees

• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE
• BIONTECH SE · DE

Inventors

• Ugur Sahin · Mainz, DE
• Sebastian Kreiter · Mainz, DE
• Mustafa Diken · Mainz, DE
• Jan Diekmann · Mainz, DE
• Michael Koslowski · Mainz, DE
• Cedrik Britten · Mainz, DE
• John Castle · Seattle, US
• Martin Löwer · Bodenheim, DE
• Bernhard Renard · Mainz, DE
• Tana Omokoko · Mainz, DE
• Johannes Hendrikus De Graaf · Lörzweiler, DE

Key dates

• Filing date: Jul 2, 2020
• Grant date: Feb 15, 2022
• Expiry date: Jul 2, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.